switching from semaglutide to tirzepatide reviews vs Semaglutide: Weight Loss, Side Effects, Uses Switching From Tirzepatide to Semaglutide:

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al

Argenxs FcRn inhibitor Vyvgart (Efgartigimod), approved in December 2021, entered the billion-dollar club by 2023

obesity is not a temporary problem, said Dorothea Vafiadis, a senior strategist for healthy aging at the National Council on Aging

52 : 8994 Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ

Ongoing nausea beyond 24 weeks that impairs nutrition or function

The lean mass losses observed are broadly consistent with what you'd expect from equivalent caloric restriction, though the researchers noted that GLP-1 medicines have a distinct effect on the muscle proteome compared to calorie restriction alone